What Is Motixafortide? Definition and What Research Reports

Definition

Motixafortide is a synthetic peptide antagonist of the chemokine receptor CXCR4 — the receptor for the chemokine CXCL12 (also called SDF-1) — and it appears throughout the literature under the development code BL-8040 (earlier: BKT140, 4F-benzoyl-TN14003). Because CXCL12–CXCR4 signalling is one of the main anchors holding haematopoietic stem cells inside the bone marrow niche, a peptide that occupies CXCR4 has been studied as a way to release those cells into the bloodstream, where they can be collected by apheresis. A review of mobilisation strategies described motixafortide as a novel CXCR4 inhibitor developed for that purpose (PMID 37250913). The same receptor axis is implicated in tumour biology and immune-cell trafficking, which is why the molecule also appears in oncology combination trials.

Molecule Class and Origin

Motixafortide is a short, chemically manufactured peptide — it is not extracted from a human or animal source and it is not a monoclonal antibody or a small-molecule drug in the conventional sense. It belongs to the family of peptide CXCR4 ligands that grew out of earlier CXCR4-binding peptide scaffolds, and it is administered by subcutaneous injection in the clinical settings where it has been evaluated. A structural study used computational and structural approaches to characterise how motixafortide (BL-8040) binds within the CXCR4 chemokine receptor, describing the binding mode of the compound at the receptor (PMID 36901829). That receptor-level description is the usual starting point for how the term is defined in pharmacology texts: a peptide antagonist that competes with the natural chemokine for the CXCR4 binding pocket.

Names and Related Terms

How the Term Is Used in Peptide Research

In peptide literature, motixafortide is normally cited as a worked example of a therapeutic peptide that reached regulatory approval, rather than as a research-only compound. A "First Approval" review recorded that motixafortide is a CXCR4 antagonist approved in the United States in 2023 for use in combination with filgrastim to mobilise haematopoietic stem cells for collection and subsequent autologous transplantation in patients with multiple myeloma (PMID 37996648). Writers therefore use the word in three recurring contexts: (1) as a named CXCR4 antagonist in discussions of the CXCL12–CXCR4 axis; (2) as a comparator or component in haematology mobilisation regimens; and (3) as an immunomodulatory partner in early-phase oncology combinations. It is a prescription product in the approved setting and is not a general-purpose research peptide.

What the Published Literature Reports

Stem-cell mobilisation in multiple myeloma

The largest dataset comes from a randomised phase 3 trial in which researchers compared motixafortide plus G-CSF against placebo plus G-CSF for mobilising haematopoietic stem cells before autologous transplantation in multiple myeloma, and the study reported that a substantially higher proportion of patients in the motixafortide arm reached the target CD34+ cell yield within the pre-specified number of apheresis sessions (PMID 37069359). A narrative review placed that result in the context of existing mobilisation practice and discussed motixafortide as an innovation in the field of haematopoietic stem-cell mobilisation (PMID 37250913). A later single-centre real-world analysis compared motixafortide with plerixafor for stem-cell mobilisation and collection in multiple myeloma and reported outcomes for the two approaches in routine practice (PMID 42435378).

Oncology combinations

Outside mobilisation, motixafortide has been tested as part of combination regimens. The COMBAT/KEYNOTE-202 trial evaluated motixafortide together with pembrolizumab added to nanoliposomal irinotecan, fluorouracil and folinic acid in metastatic pancreatic cancer, and the investigators reported antitumour activity and safety findings for that combination in previously treated patients (PMID 34253578). In the phase I/IIb MORPHEUS-PDAC umbrella study, researchers assessed atezolizumab combined with motixafortide, cobimetinib or simlukafusp alfa in pretreated advanced pancreatic cancer and reported efficacy and tolerability results across those arms (PMID 41741368). In acute myeloid leukaemia, a study examined inhibition of high CXCR4 expression with motixafortide alongside single-cell measurable residual disease assessment and reported that these measures related to outcome after AML consolidation (PMID 41980027).

Analytical and preclinical pharmacology

Method-development work also references the peptide directly: a 2025 paper described the development and validation of an LC-MS/MS method for the simultaneous estimation of motixafortide and filgrastim in rat plasma and applied it to pharmacokinetic study in that species (PMID 40420423). Such papers are the reason the term appears in bioanalytical and pharmacokinetics literature as well as in clinical haematology.

Adverse Events in Trials: What Studies Report

Safety information for motixafortide in the published record comes from its trials rather than from any general peptide literature. In the randomised phase 3 mobilisation trial, the authors reported that treatment-emergent adverse events in the motixafortide arm were predominantly transient reactions at the injection site (PMID 37069359). The First Approval review summarised the safety profile recorded during the clinical development programme that supported approval in combination with filgrastim (PMID 37996648), and the mobilisation review discussed tolerability alongside efficacy when comparing motixafortide with established mobilisation approaches (PMID 37250913). In the oncology setting, adverse events were reported in the context of multi-agent regimens, meaning the contribution of any single component cannot be isolated from the combination (PMID 34253578). This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question, medication or treatment decision.

Common Points of Confusion

• Motixafortide is not a "wellness" or "research chemical" peptide. It is a prescription product in its approved indication, given in a transplant or oncology setting under specialist supervision (PMID 37996648).
• It is not the same as G-CSF. Filgrastim is a growth factor; motixafortide is a receptor antagonist, and the phase 3 trial studied them together rather than as alternatives (PMID 37069359).
• BL-8040 and motixafortide are the same molecule. Older papers, including the pancreatic cancer combination trial, use the development code (PMID 34253578).
• Approval in one indication is not evidence in others. The oncology work in pancreatic cancer and AML remains investigational in the cited reports (PMID 41741368, PMID 41980027).

Summary

As a glossary term, motixafortide means: a synthetic peptide CXCR4 antagonist, also known as BL-8040, whose binding mode at the CXCR4 receptor has been structurally characterised (PMID 36901829), and which researchers evaluated most extensively for haematopoietic stem-cell mobilisation in combination with G-CSF in a randomised phase 3 trial (PMID 37069359). Its remaining published footprint sits in early-phase oncology combinations and bioanalytical pharmacokinetic work.

References

• Motixafortide: First Approval (Drugs, 2023)
• Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial (Nature Medicine, 2023)
• Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial (Clinical Cancer Research, 2021)
• Inhibition of high CXCR4 with motixafortide and absence of single-cell MRD predict outcome after AML consolidation (Blood, 2026)
• Atezolizumab and motixafortide, cobimetinib or simlukafusp alfa in pretreated advanced pancreatic cancer: phase I/IIb MORPHEUS-PDAC umbrella study (The Oncologist, 2026)
• Innovations in hematopoietic stem-cell mobilization: a review of the novel CXCR4 inhibitor motixafortide (Therapeutic Advances in Hematology, 2023)
• Development and Validation of the LC-MS/MS Method and Its Application for Pharmacokinetic Studies for the Simultaneous Estimation of Motixafortide and Filgrastim in rat Plasma (Biomedical Chromatography, 2025)
• Structural Basis of the Binding Mode of the Antineoplastic Compound Motixafortide (BL-8040) in the CXCR4 Chemokine Receptor (International Journal of Molecular Sciences, 2023)
• Comparative analysis of motixafortide versus plerixafor for stem cell mobilization and collection in multiple myeloma: A single center real-world experience (Transfusion, 2026)